Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Drug Delivery across the Blood–Brain Barrier: Latest Advances and Prospects
share announcement

Drug Delivery across the Blood–Brain Barrier: Latest Advances and Prospects

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 4644

Special Issue Editor

Prof. Dr. Sergey Shityakov

E-Mail Website
Guest Editor
Infochemistry Scientific Center, ITMO University, Lomonosova str, 9, Saint-Petersburg 191002, Russia
Interests: blood–brain barrier; molecular modeling; biomedicine

Special Issue Information

Dear Colleagues,

The structural and physiological properties of the blood–brain barrier (BBB) present a challenging obstacle to drug delivery to the central nervous system (CNS), limiting the treatment of many CNS diseases. The therapeutic molecule must reach the target cell in a sufficient concentration and in a suitable time frame in order for the treatment to be effective. Different approaches to improve delivery and circumvent the BBB may be local, regional, or global, and can be simulated by using in silico, in vitro, and in vivo models to understand and improve the specific mechanisms of drug permeation across the BBB. Overall, these experimental and theoretical techniques and strategies at different levels of complexity could provide new insights and future directions for diagnosis, treatment improvement, and a deeper understanding of BBB-related neuropathological events.

Prof. Dr. Sergey Shityakov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood–brain barrier
  • molecular modeling
  • biomedicine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

44 pages, 1981 KiB  
Review
Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date
by Bwalya Angel Witika, Madan Sai Poka, Patrick Hulisani Demana, Scott Kaba Matafwali, Siyabonga Melamane, Sandile Maswazi Malungelo Khamanga and Pedzisai Anotida Makoni
Pharmaceutics 2022, 14(4), 836; https://doi.org/10.3390/pharmaceutics14040836 - 11 Apr 2022
Cited by 19 | Viewed by 4113
Abstract
Neurodegenerative disorders including Alzheimer’s, Parkinson’s, and dementia are chronic and advanced diseases that are associated with loss of neurons and other related pathologies. Furthermore, these disorders involve structural and functional defections of the blood-brain barrier (BBB). Consequently, advances in medicines and therapeutics have [...] Read more.
Neurodegenerative disorders including Alzheimer’s, Parkinson’s, and dementia are chronic and advanced diseases that are associated with loss of neurons and other related pathologies. Furthermore, these disorders involve structural and functional defections of the blood-brain barrier (BBB). Consequently, advances in medicines and therapeutics have led to a better appreciation of various pathways associated with the development of neurodegenerative disorders, thus focusing on drug discovery and research for targeted drug therapy to the central nervous system (CNS). Although the BBB functions as a shield to prevent toxins in the blood from reaching the brain, drug delivery to the CNS is hindered by its presence. Owing to this, various formulation approaches, including the use of lipid-based nanocarriers, have been proposed to address shortcomings related to BBB permeation in CNS-targeted therapy, thus showing the potential of these carriers for translation into clinical use. Nevertheless, to date, none of these nanocarriers has been granted market authorization following the successful completion of all stages of clinical trials. While the aforementioned benefits of using lipid-based carriers underscores the need to fast-track their translational development into clinical practice, technological advances need to be initiated to achieve appropriate capacity for scale-up and the production of affordable dosage forms. Full article
(This article belongs to the Special Issue Drug Delivery across the Blood–Brain Barrier: Latest Advances and Prospects)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop